Tran, Chris

Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science

Prostate Cancer Treatment and ResearchHeterocyclic Compound Synthesis and Bioactivity

Cited by 2,292

Molecular determinants of resistance to antiandrogen therapy

Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine

Prostate Cancer Treatment and ResearchEstrogen and related hormone effects

Cited by 2,278

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine

PI3K/AKT/mTOR signaling in cancerCancer, Hypoxia, and Metabolism

Cited by 604

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L. (2004) · Cancer Cell

Prostate Cancer Treatment and ResearchHER2/EGFR in Cancer Research

Cited by 344